What comes next Eli Lilly says it plans to launch more than six additional Phase 3 trials in 2026 to further test retatrutide across different patient groups
Healthcare professionals and patients are encouraged to report any suspected adverse reactions, contributing to ongoing pharmacovigilance efforts
When you stop taking GLP-1 medication, your appetite signals may return to previous levels, which can lead to weight regain if healthy habits aren't maintained
Efficient Checkout Process: The company offers an easy purchasing process with various payment methods such as credit cards, Zelle, Venmo, and Cash App
For laboratories and independent researchers, understanding the nuances of the GLP-1 research peptide is essential for maintaining experimental integrity and achieving reproducible data
Patients taking tirzepatide 10 mg achieved an average of 19.5% weight loss, and patients taking tirzepatide 15 mg achieved an average of 20.9% weight loss